Investigate The Relationship Between Abnormal Thyroid Function and Benign or Malignant Breast Tumors_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 HUYue ¹ , SUNChao ² ,  DilimulatiAisimutula ¹ , LUANMei-xiang ¹

1. Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China;
2. Health Team of 69241 Army, Jimsar County 831700, Changji City, Xinjiang Uygur Autonomous Region, China;

Corresponding?author：

DilimulatiAisimutula, Email: 602031587@qq.com

Keywords：

Breast cancer; Benign breast neoplasm; Abnormal thyroid function

DOI：

10.7507/1007-9424.20150320

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the correlation between abnormal thyroid function and benign or malignant breast tumors. Methods The contents of free iodine three original acid (FT3), three iodine original acid (T3), thyroxine (T4), free thyroxine (FT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin antibodies (Anti-TG), and antithyroid peroxidase antibody (Anti-TPO) were detected by chemiluminescence method in 563 patients with benign breast neoplasms, 87 patients with breast cancer, and 123 health examination population. Results T3 and T4 levels in patients with breast cancer were lower than those of normal control group and benign tumor group (P < 0.05). However, there were no significant difference in the levels of FT3, FT4, and TSH between the 3 groups (P > 0.05). The positive rates of Anti-TPO and Anti-TG were higher than those of benign group and normal group (P < 0.001). T3 and T4 levels in patients with breast cancer were not related to the expression of ER and PR, in Her-2 negative expression and lymph node metastasis were relatively low (P < 0.05). Conclusion The decrease of contents of T3 and T4, and the positive expressions of Anti-TPO and Anti-TG may provide a basis for predicting the incidence of breast cancer.

Citation： HUYue, SUNChao, DilimulatiAisimutula, LUANMei-xiang. Investigate The Relationship Between Abnormal Thyroid Function and Benign or Malignant Breast Tumors. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(10): 1240-1243. doi: 10.7507/1007-9424.20150320 Copy

1.	Zbuk K, Anand SS. Declining incidence of breast cacner after decreased use of hormone-replacement therapy:magnitude and time lags in different countries. J Epidemiol Community Health, 2012, 66(1):1-7.
2.	張敏璐, 黃哲宙, 鄭瑩.中國年女性乳腺癌發病、死亡和患病情況的估計及預測.中華流行病學雜志, 2012, 33(10):1049-1051.
3.	趙艷杰, 王睿斌, 宋光雨, 等.乳腺癌與甲狀腺疾病相關性的臨床研究.腫瘤研究與臨床, 2013, 25(3):178-180.
4.	楊紓旖, 地力木拉提·艾斯木吐拉, 王永高, 等.甲狀腺特異性抗體與乳腺癌相關性研究的系統評價.現代生物醫學進展, 2014, 14(6):1170-1173.
5.	Ergür AT, Taner Y, Ata E, et al. Neurocognitive functions in children and adolescents with subclinical hypothyroidism. J Clin Res Pediatr Endocrinol, 2012, 4(1):21-24.
6.	吳萬敏, 張艷.乳腺癌中THRβ1表達與甲狀腺激素改變的臨床研究.臨床和實驗醫學雜志, 2014, 13(18):1513-1517.
7.	Ryan J, Curran CE, Hennessy E, et al. The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One, 2011, 6(1):e16023.
8.	Kilbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated ¹²⁵I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab, 2000, 85(3):1245-1250.
9.	馬科航, 楊亮.甲狀腺疾病患者血清三碘甲腺原氨酸、甲狀腺素和促甲狀腺素的檢測分析.現代診斷與治療, 2014, 25(8):1872-1873.
10.	G?rtner R, Rank P, Ander B. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (A thens), 2010, 9(1):60-66.
11.	Huang J, Jin L, Ji G, et al. Implication from thyroid funciation decreasing during chemotherapy in breast cancer patients:chemosensitization role of triiodothyroine. BMC Cancer, 2013, 13:334.
12.	Ni Y, He X, Chen J, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet, 2012, 21(2):300-310.
13.	Tosovic A, Becker C, Bondeson AG, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer, 2012, 131(9):2126-2133.
14.	Sar P, Peter R, Rath B, et al. 3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements. PLoS One, 2011, 6(6):e20861.
15.	Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene, 2002, 21(5):761-768.
16.	Conde SJ, Luvizotto Rde A, de Síbio MT, et al. Thyroid hormone status interferes with estrogen target gene expression in breast cancer samples in menopausal women. ISRN Endocrinol, 2014, 2014:317398.
17.	Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels are positively associated with breast caJlcer risk in postmenopausal women. Breast Cancer Res, 2010, 12(3):R33.
18.	夏敏玲, 陳思佳.乳腺癌患者血清甲狀腺激素水平檢測及其臨床意義.中國病案, 2011, 12(10):68-69.
19.	高瑩, 李秀珍, 張玥, 等.低T3綜合征與危重癥.中華全科醫學, 2013, 11(12):1858-1859.
20.	Kuijpens JL, Nyklíctek I, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid, 2005, 15(11):1253-1259.
21.	Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol, 2001, 27(7):626-630.
22.	Smyth PP. Autoimmune thyroid disease and breast cancer:a chance association. Endocrinol Invest, 2000, 23(1):42-43.
23.	Hsu SF, Goan YG, Tsai HY, et al. An upstream regulatory element confers orientation independent enhancement of the TSG101 promoter activity in transformed cells. Mol Biol Rep, 2012, 39(1):517-525.
24.	Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res, 2003, 5(5):235-238.
25.	Eskes SA, Endert E, Fliers E, et al. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol, 2014, 80(3):444-451.
26.	Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol, 2004, 150(5):605-618.
27.	Tosovic A, Becker C, Bondeson AG, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer, 2012, 131(19):2126-2133.
28.	Prinzi N, Baldini E, Sorrenti S, et al. Prevalence of breast cancer in thyroid diseases:results of a cross-sectional study of 3921 patients. Breast Cancer Res Treat, 2014, 144(3):683-688.

1. Zbuk K, Anand SS. Declining incidence of breast cacner after decreased use of hormone-replacement therapy:magnitude and time lags in different countries. J Epidemiol Community Health, 2012, 66(1):1-7.
2. 張敏璐, 黃哲宙, 鄭瑩.中國年女性乳腺癌發病、死亡和患病情況的估計及預測.中華流行病學雜志, 2012, 33(10):1049-1051.
3. 趙艷杰, 王睿斌, 宋光雨, 等.乳腺癌與甲狀腺疾病相關性的臨床研究.腫瘤研究與臨床, 2013, 25(3):178-180.
4. 楊紓旖, 地力木拉提·艾斯木吐拉, 王永高, 等.甲狀腺特異性抗體與乳腺癌相關性研究的系統評價.現代生物醫學進展, 2014, 14(6):1170-1173.
5. Ergür AT, Taner Y, Ata E, et al. Neurocognitive functions in children and adolescents with subclinical hypothyroidism. J Clin Res Pediatr Endocrinol, 2012, 4(1):21-24.
6. 吳萬敏, 張艷.乳腺癌中THRβ1表達與甲狀腺激素改變的臨床研究.臨床和實驗醫學雜志, 2014, 13(18):1513-1517.
7. Ryan J, Curran CE, Hennessy E, et al. The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One, 2011, 6(1):e16023.
8. Kilbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated ¹²⁵I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab, 2000, 85(3):1245-1250.
9. 馬科航, 楊亮.甲狀腺疾病患者血清三碘甲腺原氨酸、甲狀腺素和促甲狀腺素的檢測分析.現代診斷與治療, 2014, 25(8):1872-1873.
10. G?rtner R, Rank P, Ander B. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (A thens), 2010, 9(1):60-66.
11. Huang J, Jin L, Ji G, et al. Implication from thyroid funciation decreasing during chemotherapy in breast cancer patients:chemosensitization role of triiodothyroine. BMC Cancer, 2013, 13:334.
12. Ni Y, He X, Chen J, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet, 2012, 21(2):300-310.
13. Tosovic A, Becker C, Bondeson AG, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer, 2012, 131(9):2126-2133.
14. Sar P, Peter R, Rath B, et al. 3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements. PLoS One, 2011, 6(6):e20861.
15. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene, 2002, 21(5):761-768.
16. Conde SJ, Luvizotto Rde A, de Síbio MT, et al. Thyroid hormone status interferes with estrogen target gene expression in breast cancer samples in menopausal women. ISRN Endocrinol, 2014, 2014:317398.
17. Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels are positively associated with breast caJlcer risk in postmenopausal women. Breast Cancer Res, 2010, 12(3):R33.
18. 夏敏玲, 陳思佳.乳腺癌患者血清甲狀腺激素水平檢測及其臨床意義.中國病案, 2011, 12(10):68-69.
19. 高瑩, 李秀珍, 張玥, 等.低T3綜合征與危重癥.中華全科醫學, 2013, 11(12):1858-1859.
20. Kuijpens JL, Nyklíctek I, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid, 2005, 15(11):1253-1259.
21. Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol, 2001, 27(7):626-630.
22. Smyth PP. Autoimmune thyroid disease and breast cancer:a chance association. Endocrinol Invest, 2000, 23(1):42-43.
23. Hsu SF, Goan YG, Tsai HY, et al. An upstream regulatory element confers orientation independent enhancement of the TSG101 promoter activity in transformed cells. Mol Biol Rep, 2012, 39(1):517-525.
24. Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res, 2003, 5(5):235-238.
25. Eskes SA, Endert E, Fliers E, et al. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol, 2014, 80(3):444-451.
26. Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol, 2004, 150(5):605-618.
27. Tosovic A, Becker C, Bondeson AG, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer, 2012, 131(19):2126-2133.
28. Prinzi N, Baldini E, Sorrenti S, et al. Prevalence of breast cancer in thyroid diseases:results of a cross-sectional study of 3921 patients. Breast Cancer Res Treat, 2014, 144(3):683-688.

Previous Article
Effect Analysis on 3DMax Patch and Plain Film Applied to TAPP Treatment of Inguinal Hernia
Next Article
21例腸系膜上動脈壓迫綜合征診治體會

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Investigate The Relationship Between Abnormal Thyroid Function and Benign or Malignant Breast Tumors

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content